CNS Pharmaceuticals (NASDAQ: CNSP) has been developing drug candidates for treating primary and metastatic brain and central nervous system cancer. “Berubicin, the company’s lead drug candidate, is a novel anthracycline in an ongoing international trail in glioblastoma (“GBM”) treatment. The interim analysis data from this potentially pivotal trial is expected in mid-2023… Berubicin was the first [anthracycline] to provide scientific data which appears to demonstrate its ability to cross the blood-brain barrier and was designed with a molecular target of topoisomerase II enzymes responsible for cleaving and recombing double-stranded DNA during cellular replication,” a recent article explains. “Since the beginning of 2022, CNS Pharmaceuticals has completed pivotal milestones with Berubicin, receiving approval from Switzerland Ethics Committee (‘EC’) and Competent Authority (‘CA’), France EC and CA, and Spain EC and CA to open sites. The company’s next steps include pivotal trial expansions into additional countries, expected completion of enrollment, interim analysis/data, and target topline results from the potentially pivotal study… ‘We are at the point where the finish line is within sight, and that is: ‘Is this drug performing in a clinical setting the way we want it to?’ And if it is, there is nothing to compete with it,’ CNS Pharmaceuticals CEO John Climaco commented.”
To view the full article, visit https://ibn.fm/Fu0ZL
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Additionally, the company is advancing the development of its WP1244 drug technology portfolio, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of the WP1244 portfolio in the treatment of brain cancers, pancreatic, ovarian, and lymphomas. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
